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Abstract
Background: Activation of the A2A adenosine receptor (A2AAR) decreases production of inflammatory cytokines,
prevents C. difficile toxin A-induced enteritis and, in combination with antibiotics, increases survival from sepsis in
mice. We investigated whether A2AAR activation improves and A2AAR deletion worsens outcomes in a murine
model of C. difficile (strain VPI10463) infection (CDI).
Methods: C57BL/6 mice were pretreated with an antibiotic cocktail prior to infection and then treated with
vancomycin with or without an A2AAR agonist. A2AAR
-/- and littermate wild-type (WT) mice were similarly infected,
and IFNγ and TNFα were measured at peak of and recovery from infection.
Results: Infected, untreated mice rapidly lost weight, developed diarrhea, and had mortality rates of 50-60%.
Infected mice treated with vancomycin had less weight loss and diarrhea during antibiotic treatment but mortality
increased to near 100% after discontinuation of antibiotics. Infected mice treated with both vancomycin and an
A2AAR agonist, either ATL370 or ATL1222, had minimal weight loss and better long-term survival than mice treated
with vancomycin alone. A2AAR KO mice were more susceptible than WT mice to death from CDI. Increases in cecal
IFNγ and blood TNFα were pronounced in the absence of A2AARs.
Conclusion: In a murine model of CDI, vancomycin treatment resulted in reduced weight loss and diarrhea during
acute infection, but high recurrence and late-onset death, with overall mortality being worse than untreated infected
controls. The administration of vancomycin plus an A2AAR agonist reduced inflammation and improved survival rates,
suggesting a possible benefit of A2AAR agonists in the management of CDI to prevent recurrent disease.
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Background
Clostridium difficile infection (CDI) is characterized
by intense intestinal and systemic inflammatory reac-
tions, especially in moderate to severe disease. Such
microorganism-initiated tissue damage causes de novo pro-
duction and in situ accumulation of adenosine that signals
through four G protein–coupled receptors designated as
A1, A2A, A2B, and A3 [1]. Activation of the A2A adenosine
receptor (A2AAR) produces a constellation of responses
that are anti-inflammatory. Pro-inflammatory responses in
bone marrow derived cells (BMDC) including platelets [2],
monocytes [3], mast cells [4,5], neutrophils [6-8] and T
cells [9-11] are all inhibited by A2AAR activation.
Adenosine is a purine nucleoside that plays an import-
ant role in many biochemical processes such as energy
transfer. It also acts as a secondary messenger and neuro-
transmitter [12]. Endogenous adenosine is produced in
part by nucleotide degradation with participation of 50
nucleotidase with or without ectonucleotidases on cell
membranes, from the pool of adenosine triphosphate
(ATP), adenosine diphosphate (ADP), or adenosine mono-
phosphate (AMP) released through regulatory processes,
inflammation, or cellular damage. Adenosine can further
be degraded to inosine by adenosine deaminase intra-
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and/or extra-cellularly. Otherwise, it can be retaken up
and converted back to AMP by adenosine kinase. As an
endogenous purine nucleotide, adenosine modulates many
physiological processes through four adenosine receptor
subtypes, A1, A2A, A2B and A3.
Selective activation of the A2AAR with synthetic ad-
enosine analogs has been demonstrated to protect many
tissues, including liver, kidney, skin, heart, and spinal
cord, from ischemia-reperfusion injury [13-16], to inhibit
inflammatory responses in rabbit joint sepsis induced by
LPS [17], and to improve mouse survival from sepsis
with Escherichia coli [18,19] or Staphylococcus aureus
[18] in combination with antibiotic treatment. Previous
studies have suggested that activation of A2AARs with
ATL 313, or inhibition of adenosine deaminase prevents
Clostridium difficile toxin A-induced enteritis by redu-
cing the production of inflammatory cytokines in mouse
or rabbit ileal loop model [20-22]. In the current study,
we found that A2AAR activation during antibiotic treat-
ment for CDI lessens disease severity, prevents relapse
and increases survival of mice. Deletion of A2AARs wor-
sens outcome of CDI by enhancing the host inflamma-
tory response to infection. The beneficial effects of A2AR
activation are probably caused by anti-inflammatory
effects of A2AAR activation counteracting the pro-
inflammatory effects of C. difficile toxins.
Methods
Animals
Eight-week old male C57BL/6 mice were purchased from
the Jackson Laboratory (Bar Harbor, ME 04609). Food and
water were provided ad libitum before and during the
experiments. A2AAR -/- mice from Jiang-Fan Chen [23] of
Boston University were bred to be congenic with C57BL/6
mice. A2AAR -/- mice were age- and sex-matched to wild
type controls. Mouse genotyping employed a set of 3 pri-
mers (50-GGGCTCCTCGGTGTACAT-30, 50-CCCACAG
ATCTAGCCTTA-30, 50-TGTCACGTCCTGCACGAC-30)
to resolve a 380-bp wild type allele versus a 500-bp
knockout allele. Animals were housed in a pathogen-free
isolation barrier facility with chip bedding. A previously
published infection model was adapted with slight modifi-
cation [24]. Briefly, all mice were started with a 3-day
antibiotic cocktail pretreatment containing 4.5 mg of
vancomycin, 4.2 units of colistin, 3.5 mg of gentamicin, and
21.5 mg of metronidazole per kg/day in drinking water 6
days before the infection. Clindamycin (32 mg/kg) was
given intraperitoneally to each mouse the day before the in-
fection. Mice were transferred from a pathogen-free room
to a BSL-2 room within the vivarium where they were pre-
pared for infection. Infected mice remained in the same
cage and were placed in a dedicated sash in the BSL-2
room. In most experiments, 50 mg/kg/day of vancomycin
was administered in drinking water starting 24 hours post
infection. The vancomycin treatment was routinely termi-
nated on day 4 post infection unless specifically stated.
Treatment with an A2AAR agonist (via Alzet pump as
described below) was typically started 1 day post-infection
(unless specified) and lasted for either 7 or 14 days. Mice
that were considered moribund were euthanized by cer-
vical dislocation. Infection and treatment protocol was
approved by the University of Virginia Animal Care and
Use Committee.
Materials
The A2AAR agonists ATL370 and ATL1222 as well as
ALZET mini-osmotic pumps (Model 1007D and 1002) were
gifts from Dogwood Pharmaceuticals, Inc (Charlottesville,
VA). The chemical structure and molecular weight of
ATL370 are shown in Figure 1. The molecular weight of the
ATL370 analogue, ATL1222, is 539.25 and its potency at the
adenosine receptor subtypes is similar to ATL370. Injectable
vancomycin hydrochloride (Hospira, Inc., Lake Forest, IL),
Colistimethate (Colistin) (X-GEN Pharmaceuticals, Inc.,
Big Flats, NY), gentamicin sulfate (Hospira), metronidazole
(Flagyl) (Baxter Healthcare Corporation, Deerfield, IL), and
cleocin phosphate (clindamycin) (Pharmacia and Upjohn
Company, Bridgewater, NJ) were all purchased through the
Figure 1 Molecular Structure and Weight of A2AAR Agonist, ATL370.
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University of Virginia Hospital Pharmacy. C. difficile strain
VPI10463 was purchased from American Type Culture
Collection (Manassas, VA). Chopped Meat Broth (CM,
catalog AS-811) for Clostridium difficile growth was pur-
chased from Anaerobe Systems (Morgan Hill, CA). Bacto
Brain Heart Infusion (BHI medium) for C. difficile wash
and reconstitution was purchased from BD Medical-
Pharmaceutical Systems (Franklin Lakes, NJ). Bouin’s fixa-
tive was purchased from Polysciences, Inc. (Warrington,
PA). QIAamp DNA Stool Mini Kit and Proteinase K were
purchased from Qiagen, Inc. (Valencia, CA). iQ SYBR
Green Supermix containing dNTPs, iTaq DNA polymer-
ase, 6mM MgCl2, SYBR Green I, fluorescein, and stabili-
zers was obtained from Bio-Rad Laboratories (Hercules,
CA). All PCR primers were ordered through Integrated
DNATechnologies, Inc. (Coralville, IA).
Radioligand binding assays
The adenosine receptor binding assay methodology has
been described previously [8] and was conducted by
Dogwood Pharmaceuticals (Charlottesville, VA 22911).
In brief, all subtypes of recombinant human and mouse
ARs were stably expressed in HEK-293 cells (A2AAR,
A2BAR, and A3AR), CHO-K1 cells (A1AR) or transiently
expressed by baculoviral infection of Sf9 cells (A2AAR,
high-affinity assay). Crude membranes were prepared
from these transfected cells. An appropriate radioligand
(125I-ABA for A1AR and A3AR,
125I-ZM241385 for
A2AAR,
125I-ABOPX for A2B AR, or
125I-APE for A2AAR/
high affinity assay) was added, then filtered through glass
fiber filters, and counted in a Wallac Wizard 1470 gamma
counter (Perkin Elmer, Boston MA). The non-specific
binding of radiolabeled ligand was measured in the pres-
ence of the non-selective AR agonist, NECA (100 μM). G
protein coupled receptors bound agonists with two affinity
states (G protein coupled and G protein uncoupled). The
coupled high affinity state was the more relevant assay
because it reflects the active configuration of the receptor.
To produce G protein coupled human A2AARs, Sf9 cells
were simultaneously infected with 4 baculoviruses
encoding the human A2AAR and G protein αs, β4 and
γ2 subunits [25]. High affinity binding was performed
using 125I-APE as described above. Competition binding
curves were constructed and IC50 values calculated using
a 4-parameter logistic fit (PRISM 5.0, GraphPad Software,
San Diego, CA). The value of Ki for competition for
radioligand binding by agonist was calculated using
the Cheng-Prusoff equation [26]. Ki values were cal-
culated from the mean of triplicate or quadruplicate
assays and normalized to the mean value of the
inter-assay standard.
Preparation of Clostridium difficile inocula
C. difficile was grown for 20 hours in CMB (37°C),
transferred to a fresh tube of CMB and incubated for 5
hours to achieve log-phase growth prior to infection.
Bacteria were centrifuged at 10,000 rpm for 2 minutes,
washed with BHI medium three times, reconstituted
with BHI medium, and quantified by spectrophotometry.
An OD reading of 1.0 was calculated to be equivalent to
5×107 cfu C. difficile/ml. The final concentration of C.
difficile (cfu/ml) was validated by hemocytometer read-
ing under light microscopy. Unless the dose was specif-
ically stated, 1×104-5 of C. difficile was gavaged to each
mouse in the infected groups, and BHI medium only
was given to mice in uninfected groups.
Implantation of ALZET osmotic pumps
ALZET mini-osmotic pumps (Model 1007D and 1002)
were implanted in mice using a protocol approved by the
University of Virginia Animal Care and Use Committee.
Briefly, mice were anesthetized with a mixture of ketamine
and xylazine and placed on a heating pad. A short (~5
mm) incision was made at the interscapular area after
shaving and cleaning the skin with 70% ethanol and iod-
ine. Pumps filled with A2AAR agonists (ATL370 or
ATL1222 at either 1 or 10 ng/kg/min) for treated mice or
an equivalent amount of the vehicle-3% dimethyl sulfoxide
(DMSO) in PBS only, for untreated control mice were
inserted subcutaneously. A wound clip was used to close
the incision. Mice were allowed to wake up on the heating
pad before returning to the BSL2 sash.
Clinical scoring system
During the entire post infection period, daily weights and
clinical scores were recorded for each mouse (Table 1).
Table 1 Clinical scoring system for mice infected with Clostridium difficile
Category Scores*
0 1 2 3
Activity normal Alert/slow moving Lethargic/shaky Inactive unless prodded
Posture normal Back slanted Hunched Hunched/nose down
Coat normal Piloerection Rough skin Very ruffled/puff/ Ungroomed
Diarrhea normal Soft stool/discolored (yellowish) Wet stained tail/ mucous +/- blood Liquid/no stool (ileus)
Eyes/Nose normal Squinted ½ closed Squinted/discharge Closed/discharge
*Clinical Score=sum of all parameter scores. Total possible score=15. Normal=0; Found dead=15.
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The sum of all parameter scores was considered the final
clinical score and ranged from 0 (normal) to 15. Mice
judged to be moribund were sacrificed. Mice found dead
were assigned a score of 15. Stools were collected daily
and stored at -20°C until DNA extraction was performed.
Extraction of DNA from frozen mouse stools
All stool samples were weighed before DNA extraction for
sample normalization. Stool DNA was extracted under the
modified protocol provided in the QIAamp DNA Stool
Mini Kit. Briefly, frozen stool was added to 400 μL of ASL
buffer, homogenized by grinding with a wooden stick, vor-
texed for 15 seconds before and after heating in a water
bath at 82.5°C for 5 minutes, and then centrifuged at
14,000 rpm for 2 minutes. The remaining steps followed
the manufacturer’s directions. Extracted stool DNA was
stored at -20°C prior to PCR testing.
Quantification of C. difficile shedding by qPCR
C. difficile DNA was analyzed from extracted stool
DNAs with iQ SYBR Green Supermix in a 96-well plate
performed at CFX96™ Real-Time PCR Detection System
(Bio-Rad). Briefly, a PCR master mix was prepared with 23
μL aliquot containing 1 μL each of tcdB forward and re-
verse primers, 12.5 μL iQ SYBR Green Supermix, and
8.5 μL of H2O purified by Milli-Q Integral Water
Purification System (Millipore Corporation, Billerica,
MA). 2 μL of each sample was then added to each
well filled with PCR master mix aliquot in 96-well. The
PCR parameters were sequentially set for 3 stages: 1× cycle
for 5 minutes at 94.0°C, 40 × cycle for 30 seconds each
from 94.0°C and 55.0°C to72.0°C, 64 × cycle at 62.0°C for
15 seconds, and 1× cycle for hold at 25.0°C. Melt curve
data collection and analysis were enabled. Copy numbers
of unknown sample were extrapolated from the standard
curve that was generated with the extracted DNA
prepared from known C. difficile inocula. The sequence of
tcdB forward primer was 50-GGAGAGTCATCCAACTTA
TATG-30; the sequence of tcdB reverse primer was 50-
CCACCAATTTCTTTTAATGCAG-30.
Intestinal histopathology
The middle cross section of cecum and proximal cross
section of colon were harvested from moribund mice or
surviving mice at the end of the experiment. Tissues were
fixed overnight with Bouin’s solution and stored in 70%
ethanol until subsequently processed for Hematoxylin &
Eosin (HE) staining at University of Virginia Research
Histology Core. Slides were examined using a Leica
DFC425 digital camera equipped microscope with Leica
Application Suite Version 3.6.0.488 imaging software
(Leica Microsystems Inc., Buffalo Grove, IL 60089). Intes-
tinal tissues were scored from 0 to 3 (with zero as normal
and 3 as the worst pathologic score) under 5 categories:
overall architecture, mucosal thickness, submucosal edema,
inflammation, and exudates.
ELISA for IFNγ and TNFα
One set of infection experiments with A2AAR -/- (n=8)
and their littermate A2AAR +/+ (n=8) mice were set aside
for blood and tissue cytokine assays at the peak of infec-
tion (day 3) and also at recovery (day 7). Blood samples
were collected in heparinized tube by cardiopuncture
under sedation. Plasma samples were obtained by centri-
fuging blood at 10,000 rpm at room temperature for 20
minutes and stored at -80°C until further analysis. Upon
euthanasia, cecal samples were harvested and stored at
-80°C. ELISA was performed using Thermo Scientific
Pierce Mouse IFNγ and TNFα kits (Rockford, IL) with
slight modification of the manufacturer’s instruction.
Briefly, cecal tissue was homogenized by grinding on dry
ice and suspended in diluent reagent (0.2 mg/ml). Each
homogenate or plasma sample was incubated with IFNγ
antibody (for 1 hour) or TNFα antibody (for 2 hours) in
1:20 final dilution (200 μl) at room temperature. After
washing, the sample was incubated with 100 μl of
streptavidin-horseradish peroxidase (HRP) for 30 minutes.
Subsequently, 100 μl of TMB substrate was added for an-
other 30-minute incubation in the dark. The incubation
was terminated with 100 μl of stop solution. Samples were
immediately measured at 450 nm and 550 nm in Gen5
1.11.5 version in BioTek Spectrophotometer (Winooski,
Vermont). Standard curves were established by plotting
the average absorbance obtained for each standard known
concentration (pg/ml). Cytokine amount in each sample
was extrapolated from the standard curves.
Statistical analysis
Statistical analyses were conducted using GraphPad Prism
Version 5.02 software. When mouse was either found dead
or sacrificed due to severe distress, its last body weight
recording was continuously plotted against the body
weights of surviving mice. Differences between groups for
the entire experimental period were analyzed by 2-Way
ANOVA with Bonferroni post hoc testing. Survival curves
were analyzed using Log-rank (Mantel-Cox) or Log-rank
test for mortality trend.
Results
A2AAR agonist reduced diarrhea and deaths in C.
difficile- infected mice
To confirm the protective effect of A2AAR activation
previously seen in ileal loop models [20-22], we used the
A2AAR agonist ATL370 to treat wild-type mice infected
with C. difficile VPI10463. The binding affinity of ATL
370 to adenosine receptors is shown in Table 2. Two
dosing regimens were tested: ATL370 at 1 ng/kg/min via
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a 14-day (first study) and at 10 ng/kg/min via a 7-day
(2nd study) Alzet pumps. Mortality rate from infected
controls in the first study was 50%, with deaths occurring
at days 4 and 5 (Figure 2A). All mice treated with vanco-
mycin alone had relapsed and succumbed to infection by
day 11 (deaths occurred 5 to 11 days after discontinuation
of the antibiotic). In contrast, survival increased to 33% in
mice treated with both vancomycin and ATL30. From day
1 post infection, infected mice progressively lost weights
with a few losing up to almost 20% of their body weight at
baseline (Figure 2B). Infected mice treated with vanco-
mycin did not have weight loss until four days after ter-
mination of vancomycin treatment. Infected mice treated
with both vancomycin and ATL370 at 1 ng/kg/min lost
the same amount of weight as the vancomycin only-
treated mice although weight loss started one day later.
Infected control mice had rapid development of diarrhea
and elevated clinical scores (Figure 2C), whereas treat-
ment with vancomycin prevented signs of disease until
three days after termination of treatment. Consistent with
weight changes, clinical symptoms tended to be lessened
in mice receiving combination treatment compared to
those treated with vancomycin alone. Clostridial shedding
in the stool was elevated in infected mice not given
vancomycin during acute infection (data not shown).
Upon discontinuation of vancomycin, clostridial shedding
increased significantly and remained elevated with or
without ATL370 in surviving mice indicating that the
agonist does not affect fecal clostridial burden. This
experiment suggested a modest benefit of the A2AAR
agonist ATL370 at 1 ng/kg/min if given with vancomycin
during C. difficile infection. Furthermore, this study
suggested that A2AAR activation during infection is
detrimental in the absence of antibiotics.
We next tested the effect of ATL370 at a higher dose
but shorter duration of treatment, we used 10 ng/kg/min
dosing given for 7 days (via Alzet pump). Similar to what
was observed earlier, infected mice treated with vanco-
mycin fared well for several days until discontinuation
of vancomycin. Addition of ATL370 to vancomycin
improved survival by 20%. Infected mice that received
ATL370 alone had a 0% survival rate. Weight changes and
clinical scores followed the same trend as the first study.
Taken together, these data suggested that low dose
ATL370 may be as beneficial as higher doses if given with
Table 2 Characterization of the A2AAR agonist, ATL370, by radioligand binding (mean ± SD)
Receptor A1AR A2AAR - high
a A2AAR- low
a A2BAR A3AR
Radioligand 125I-ABA 125I-APE 125I-ZM241385 125I-ABOPX 125I-ABA
Human (Ki, nM) 61.1 ± 11.3 0.5 ± 0.2 3.8 ± 0.7 >10,000 130.4 ± 44.4
Mouse (Ki, nM) 65.3 ± 15.8 N/A 4.3 ± 2.8 >10,000 84.2 ± 19.2
aAgonists are known to bind to two affinity states of G-protein coupled receptors. Low affinity reflects binding to uncoupled receptors. High affinity refers to
binding to receptor-G protein complexes.





















































































Figure 2 Effect of A2AAR Agonist ATL370 on C. difficile-Infected
Mice. Mice were infected with VPI10463 at 105 inoculum and treated or
not with vancomycin (50 mg/kg/day for 3 days) with or without ATL370
(1 ng/kg/min). Each group had 6 mice each except for uninfected
control (n=4). For statistical analyses of weight change and clinical
scores, the latest value from a dead mouse was carried through to the
end of observation but not shown in the graphs. A. Survival curve.
P=0.0016 by Mantel-Cox. B. Percent weight loss from day 0 (day of
infection). *p<0.05 to 0.001 for uninfected (UC) vs. infected (I) controls,
†p<0.01 to 0.001 for I vs I with vancomycin (Vanc), ‡p<0.01 to 0.001 for I
vs. I with Vanc plus ATL370(1); by Two-way ANOVA with Bonferroni’s
correction. C. Clinical scores. *p<0.05 for UC vs. I controls, †p<0.05 for I
vs I with Vanc; by Two-way ANOVA with Bonferroni’s correction.
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vancomycin and confirmed that A2AAR agonist alone
could exacerbate disease during acute infection.
Early or delayed administration of A2AAR agonist
improved outcome of C. difficile infection
To determine whether the timing of A2AAR agonist treat-
ment would alter the response to treatment, we investi-
gated the effect of delaying administration of ATL370 in
relation to vancomycin. During the 21-day post infection
period (Figure 3), we observed a 50% survival rate in the
infected control group while those treated with vanco-
mycin alone had only a 17% survival rate. Again, mortality
in the vancomycin-treated mice was evident only after the
antibiotic was discontinued suggesting relapse of infection.
Treatment with ATL370, regardless of whether it was
started at the same time as or 3 days after vancomycin
was started, increased survival by 33%, indicating a benefit
of A2AAR activation even at a later timepoint after infec-
tion or antibiotic treatment. Body weight change, diarrhea
and clinical scores followed similar trends as shown in
previous experiments.
Reduced vancomycin exposure further increased survival
in the presence of A2AAR agonist in mice infected with
C. difficile
Given that vancomycin administration had consistently
resulted in delayed and worse mortality compared to
untreated infection, we investigated whether decreasing
duration of vancomycin treatment would improve survival
and, therefore, enhance benefit derived from A2AAR acti-
vation. As shown in Figure 4A, short treatment durations
(1-2 days) prevented recurrence of infection and signifi-
cantly improved survival rate from 37.5% in longer treat-
ment durations (3-5 days) to 87.5%. We, then, compared a
short course (2-day) versus a long course (5-day) vanco-
mycin treatment in combination with another A2AAR
agonist, ATL1222. As shown in Figure 4B, infected mice
treated with a 2-day treatment course had better survival
rates than mice treated with a 5-day course (50% vs. 25%)
of vancomycin. Furthermore, ATL1222 improved survival
by 25% when given in addition to a 2-day course of vanco-
mycin or by 50% when compared to a 5-day course of
vancomycin alone. Both weights and diarrhea scores were
likewise improved with the shorter course of antibiotics
plus ATL1222 (Figure C&D). Together, these findings sug-
gest that A2AAR activation enhances the benefit of a
shorter course of antibiotic treatment against CDI.
The absence of A2AAR worsened C. difficile infection in mice
To confirm the role of A2AAR in CDI, A2AAR knockout
(KO) and wild-type littermate mice were infected with
VPI10463. As seen in Figure 5A (Exp B), only 50% of
infected KO mice survived compared to 80% of infected
wild-type mice. Four similar experiments were performed
to compare survival rates between infected A2AAR KOs
and wild-type mice (Figure 5B). The overall survival rates
in infected wild-type were consistently higher than
infected KO mice (75% vs. 36.67%) suggesting that the ab-
sence of the A2AAR is detrimental during infection.
Regardless of their genetic background, infected ani-
mals had significantly higher total cecal histopathology
score than uninfected controls (Figure 6; Exp B). More-
over, cecal tissues from infected KO mice had higher
histopathology scores than those from wild-type mice.
Submucosal edema, mucosal thickness and inflammation
were observed more in infected than uninfected cecal
tissues (Figure 6A-D). The same parameters were worse
in A2AAR gene deleted mice than wild types during in-
fection confirming A2AAR’s protective role against
infection-induced epithelial injury consistent with what
was previously seen in toxin-induced enteritis [22].
The absence of A2AAR activation altered the inflammatory
response during CDI in mice
To determine whether enhanced inflammation contribu-
ted to the greater epithelial injury and increased mortality
in A2AAR-/- mice, cecal tissues and sera were assayed for
IFNγ and TNFα. IFNγ and TNFα levels were increased
during infection in wild-type mice at both days 3 and 7
post-infection (Figure 7). Unexpectedly, both cytokines
were significantly depressed in A2AAR-/- compared to
A
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Figure 3 Effect of Timing of A2AAR Agonist ATL370 Treatment
on C. difficile-Infected Mice. Mice were infected with VPI10463 at
105 inoculum and treated or not with vancomycin (50 mg/kg/day
for 3 days) with or without ATL370 (1 ng/kg/min started either at
day 1 or day 4 after infection). A. Survival Curve, p=0.1427 by
Mantel-Cox. B. Clinical Scores; **p<0.01 for I vs. I with Vanc, *p<0.05
to 0.01 for I vs. I with Vanc plus ATL370 by Two-way ANOVA.
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wild-type mice at day 3 suggesting less inflammation in
the absence of A2AAR at the expected peak of infection.
At day 7 post-infection, IFNγ and TNFα were significantly
more elevated in cecal and blood, respectively, in
A2AAR-/- mice than wild-type mice indicating that onset
and resolution of inflammation were both delayed in the
absence of A2AARs. Furthermore, these results suggest
that IFNγ may play a greater role in intestinal tissue injury
while TNFα may be more involved in the systemic mani-
festations of infection.
Discussion and conclusions
Vancomycin is the drug of choice for severe CDI [27,28].
However, its use has been associated with clinical recur-
rence of infection in up to 20% of cases, which has been
attributed to antibiotic-induced changes of gut micro-
biota [29]. In the mouse model of infection, recurrence
of disease and late mortality has also been observed to
occur in 40-60% of mice treated with vancomycin
[24,30]. Typically, mice treated with vancomycin remain
well and only develop disease several days after cessation
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Figure 4 Effect of A2AAR Agonist ATL1222 on Mortality of Mice Infected with C. difficile and Treated with Vancomycin of Short or Long
Duration. Mice were infected with VPI10463 at 105 inoculum. Each group had 8 mice except uninfected control (n=4). A. Mice were treated or
not with vancomycin (50 mg/kg/day) for 1, 2, 3 or 5 days. P=0.058 by Log-rank (Mantel-Cox) Test. B. Mice were treated with vancomycin for
either 2 or 5 days with or without ATL1222 (1ng/kg/min started at day 1 post-infection). P value for Log-rank (Mantel-Cox) test at 0.29. C. Weight
Change (%). D. Diarrhea score (mean). Scoring system defined in Table 1.
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of the antibiotic. In our study, we demonstrated that the
addition of A2AAR agonists during vancomycin treat-
ment decreased recurrence and associated late mortality
in mice infected with C. difficile. We then confirmed the
role of A2AARs in CDI by showing that the complete ab-
sence of A2AAR activation exacerbated disease and alter-
ation of inflammatory cytokine expression.
Intestinal epithelial cells have a very limited capacity for
de novo adenosine synthesis [31]. The villous cells can dir-
ectly use absorbed dietary nucleosides but the cryptal cells
depend on blood supply. Under normal adenosine homeo-
stasis, extracellular adenosine concentrations can be lower
than 1 μM [32,33]. In response to cellular damage, adeno-
sine concentrations are quickly elevated 100-fold higher in
inflamed intestine due to ATP and adenosine secretion in
inflammatory and other cell types. Control of inflamma-
tion and injury is thought to be secondary to A2AAR acti-
vation in intestinal tissue reperfusion injury [34] or
experimental colitis [35]. The A2AAR has been shown to
inhibit neutrophil cytotoxic activities such as expression of
β2-integrins [36], adhesion to endothelium [37], produc-
tion of oxygen radicals [38,39], degranulation [40], and
production of TNF-α [41]. Given intense intestinal inflam-
mation, including neutrophilic tissue infiltration, noted in
CDI in mouse [42], blockade or absence of A2AARs would,
then, be expected to result in aggravation of disease. In-
deed, in our study, A2AAR knockout mice had worse col-
itis (even in mice surviving infection) and more deaths
from C. difficile infection compared to wild-type litter-
mates suggesting that endogenous adenosine provides
protection against infection through the A2AAR. A2AAR
agonists added to 3 days of vancomycin treatment
improved survival, clinical scores, and cecum histopath-
ology compared to vancomycin alone when treatment was
started at least one day after the animals were infected.
This benefit was probably mediated by the anti-
inflammatory effects of A2AAR activation counteracting
the pro-inflammatory effects of C. difficile toxins.
Previous studies have shown that A2AAR activation
with ATL 313 or inhibition of adenosine deaminase
























Figure 5 Survival of A2AAR +/+ or -/- Mice Infected with C. difficile. A. Survival Curve of Exp B showing 80% of the littermate wild-type
vs. 50% of knockout mice surviving infection with VPI10463. P value for Log-rank (Mantel-Cox) Test is 0.1592; P value of Logrank test for trend
is 0.0666. B. Cumulative mortality from all experiments (Exp A-D). Number of mice in each experiment (number of mice surviving infection).
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attenuated C. difficile toxin A-induced ileitis in mice
[20,21]. Myeloperoxidase activity, TNF-α production,
cell death and histopathology were all noted to be
reduced in ileal tissues treated with ATL 313. Recently,
we showed that the A2AAR agonist, ATL370, decreased
toxin A-induced secretion and epithelial injury in rabbit
ileum and decreased KC (keratinocyte chemokine) and
IL10 levels in mouse cecal tissues [22]. In the current
study, we demonstrate that deletion of A2AARs in mice,
resulted in delayed but augmented expression of inflam-
matory cytokines, specifically IFNγ and TNFα during in-
fection suggesting that initial inflammatory response is
essential in controlling the disease. Indeed, the adminis-
tration of ATL 370 alone resulted in greater and quicker
mortality in most of the treated C. difficile-infected mice
suggesting that A2AAR activation may inhibit the natural
and beneficial early immune response initiated by infec-
tion. Furthermore, antibiotic treatment is essential to
control clostridial burden and development of severe
disease. This is consistent with what had been shown in
a mouse model of sepsis where another A2AAR agonist,
ATL 146e, was shown to reduce mortality in endotoxe-
mia from LPS but not in E. coli septicemia unless anti-
biotic was also given [19]. It is possible that adenosine is
utilized by bacteria to enhance virulence as observed in
other pathogens [43,44]. Interestingly, although infected
knockout mice had worse mortality than their infected
wild-type littermates, 50% of these mice still survived in
the absence of vancomycin treatment. Differences in in-
testinal flora (transgenic mice were bred in house) as
well as other host factors may play a role in susceptibil-


























Figure 6 Cecal Histopathology of A2AAR +/+ or -/- Mice Infected with C. difficile. Cecal tissues from surviving mice were obtained on the
day 14 post-infection. Histopathological scores were from 3 cecal tissues per group. *p<0.05 and **p<.001 by One-way ANOVA with Bonferroni’s
correction. Representative H&E stained tissues from uninfected (A) and infected (B) A2AAR +/+ and uninfected (C) and infected (D) A2AAR -/- mice.
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Our observation that A2AAR agonist alone (administered
at the start of infection) worsened outcomes possibly due
to inhibiting the natural immune response early on
prompted us to investigate whether delaying A2AAR agon-
ist treatment in addition to treating with vancomycin
would improve outcomes. We showed that delaying the
start of A2AAR agonist treatment post-infection was as
good as starting A2AAR agonist at the same time as vanco-
mycin administration suggesting benefit of A2AAR activa-
tion even at a later time during the course of infection and
antibiotic treatment. While our study showed that anti-
biotic treatment is necessary to cure infection, we also
demonstrated that overtreating with vancomycin may yield
the worst outcomes. Reducing the antibiotic treatment to 2
days improved outcomes and adding A2AAR agonist to this
regimen reduced the mortality associated with vancomycin
treatment alone by 50%. These observations may have im-
portant ramifications if they translate to the clinical setting.
If vancomycin (or antibiotic) treatment duration can be
reduced by adding an A2AAR agonist, recovery of the gut
microbiota may be facilitated and the recurrence of infec-
tion after antibiotic therapy may be improved considerably.
Although previous studies have shown that A2AAR ac-
tivation confers significant protection against C. difficile
toxin-induced ileitis and cecitis [20-22], protection
against severe disease in the mouse model of infection
seems limited. We recently reported that A2BAR inhib-
ition or deletion, even in the absence of an anti-
clostridial agent, improved outcome of CDI in mice [45].
During infection, the clostridial bacteria are localized in
the lumen and mucosal surface of the intestinal tract.
The A2BAR is the predominant adenosine receptor in
human intestinal epithelial cells [46] and thus, may have
a greater role than A2AAR in mediating local tissue in-
flammation in response to C. difficile infection. However,
A2AAR activity may be critical in controlling inflamma-
tory response from immune cells recruited to the intes-
tinal tissues and/or circulating immune cells during
severe disease. More studies are needed to elucidate the
interactions between different adenosine receptor sub-
types during enteric infection.
In conclusion, in a murine model of CDI, vancomycin
treatment resulted to reduced weight loss and diarrhea
during acute infection, but was associated with high recur-
rence and late-onset death, with overall mortality being
worse than untreated infected controls. Deletion of
A2AARs in mice worsened disease from CDI. The admin-
istration of an A2AAR agonist reduced the late mortality
associated with vancomycin use, suggesting a possible ad-
junctive benefit of A2AAR agonists in the management of
CDI to prevent recurrent disease and improve survival.
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Figure 7 Intestinal Tissue and Blood IFNγ and TNFα in C. difficile infected mice. Cecal and plasma levels of IFNγ and TNFα were measured
at days 3 and 7 post-infection in A2AAR -/- and A2AAR +/+ mice. Each bar from cecal levels represents 4 specimens (4 mice) per group. Each bar
from blood levels represents 4 specimens per group except bars representing infected mice on day 3 (n=3/group). *P<0.05 or **p<0.01 for
infected A2AAR +/+ vs. uninfected A2AAR +/+ in same day,
†p<0.05, ‡p<0.01 or #p<0.001 for infected A2AAR -/- vs. infected A2AAR +/+ in same
day; Two-way ANOVA with post-hoc Bonferroni’s correction.
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